Nasdaq ikna.

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...See All Market Activity. News + Insights. CLOSE... (IKNA). Nov. 9, 2023 at 2:09 p.m. ET on TipRanks.com. Buy Recommendation for ... Real-time last sale data for U.S. stock quotes reflect trades reported through ...Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com. Oct 18, 2022 · Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ...

Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has gone decline by -62.23 in comparison to its previous close of 4.13, however, the company has experienced a -61.58% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology,BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ... Risk Analysis Highly volatile share price over the past 3 months Earnings are forecast to decline by an average of 10.5% per year for the next 3 years Does not have a …

Nov 7, 2022 · Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ... BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Oct 5, 2022 · BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented initial clinical data from its ongoing IK-175 clinical program in urothelial carcinoma at the Society for Immunotherapy of Cancer (SITC) 37 th Annual ...

Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will doubtless be very grateful to see the share price up 60% in the...

Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ ... (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina ...He focuses on private company investments and fundraising for the firm. Mr. Draetta currently serves on the board of Chord Therapeutics and is Chief Financial Officer of Omega Alpha SPAC (NASDAQ ...BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Nov 29, 2023 · The public float for IKNA is 25.79M and currently, short sellers hold a 4.01% ratio of that float. The average trading volume of IKNA on November 29, 2023 was 174.06K shares. IKNA) stock’s latest price update. Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has dropped by -10.56 in relation to previous closing price of 1.61. Take Ikena Oncology (NASDAQ: IKNA) for instance. All in all, the company just announced today that the Food and Drug Administration (FDA) has granted a Fast Track designation for IK-930.Oct 18, 2022 · Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ... Nov 12, 2021 · BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...

Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ...Check if IKNA Stock has a Buy or Sell Evaluation. IKNA Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Ikena Oncology, Inc. News.BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...The public float for IKNA is 25.79M and currently, short sellers hold a 4.01% ratio of that float. The average trading volume of IKNA on November 29, 2023 was 174.06K shares. IKNA) stock’s latest price update. Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has dropped by -10.56 in relation to previous closing price of 1.61.Oct 1, 2021 · BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ... The stock of Ikena Oncology Inc (NASDAQ: IKNA) has decreased by -8.11 when compared to last closing price of 1.48.Despite this, the company has seen a loss of -66.99% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology ...

In the previous quarter, Ikena Oncology (NASDAQ:IKNA) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.04. Learn more on analysts' earnings estimate vs. IKNA's actual earnings.

Find the latest news headlines from Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ ... (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina ...Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)May 12, 2022 · BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... DSP Group, Inc. (NASDAQ:DSPG) is the most popular stock in this table. On the other hand Atomera Incorporated (NASDAQ: ATOM ) is the least popular one with only 5 bullish hedge fund positions.Find the latest news headlines from Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.

BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...

IKNA Edit my quotes Ikena Oncology, Inc. Common Stock (IKNA) Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Pre-Market Charts NEWS & …Formula One Group (NASDAQ:FWONA) has seen a decrease in hedge fund sentiment lately. Formula One Group (NASDAQ: FWONA ) was in 19 hedge funds' portfolios at the end of the first quarter of 2021 ...7 nov. 2023 ... (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksKludeIn I Acquisition Corp. Class A Common Stock (INKA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.In September 2022, Ikena Oncology had US$174m in cash, and was debt-free. Importantly, its cash burn was US$72m over the trailing twelve months. Therefore, from September 2022 it had 2.4 years of ...Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com. Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will doubtless be very grateful to see the share price up 60% in the...30 minutes. No description. Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms driving cancer survival and growth. Oct 7, 2021 · BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ... BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it ...

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Instagram:https://instagram. ishares exponential technologies etfagcn stocksandp 500 top stockshow to open a live forex trading account Nasdaq Fund Secondaries; Featured Solutions Nasdaq's IPO Process; ETF Listings; Nasdaq-100 Index Options; Derivatives AcademyThe latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on November 9, 2023.The analyst firm set a price target for $11.00 expecting IKNA to rise to within ... trading software bestfrt dividend Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community. vroom florida Nasdaq | IKNA U.S.: Nasdaq Ikena Oncology Inc. Watch list Set a price target alert After Hours Last Updated: Nov 9, 2023 6:00 p.m. EST Delayed quote $ 1.2500 -0.08 -6.02% …... (NASDAQ: IKNA). Levi & Korsinsky, LLP (PRNewsfoto/Levi & Korsinsky, LLP). News provided by. Levi & Korsinsky, LLP. Oct 02, 2023, 5:45 AM ET. NEW YORK ...BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, announced ...